Eli Lilly and Company (Lilly) and Dicerna Pharmaceuticals have signed a global licensing and research collaboration focused on the discovery, development and commercialization of new drugs in the areas of cardio-metabolic disease, neurodegeneration and pain.
Alexion Pharmaceuticals and Dicerna Pharmaceuticals have entered into a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases.
Stoke Therapeutics, a US-based biotechnology company focused on the development of drugs for severe genetic diseases, has raised $90m in a Series B financing round.
Private equity firm Bain Capital has joined forces with US pharma giant Pfizer to create a new biopharmaceutical company, dubbed Cerevel Therapeutics, which will focus on developing drugs for the treatment of central nervous system (CNS) disorders.
China-based biopharmaceutical firm CANbridge Pharmaceutical and global open-access biologics technology platform company WuXi Biologics have entered into a partnership for rare disease therapeutics.
FSD Pharma has signed a binding letter of intent (LOI) to acquire Therapix Biosciences, a NASDAQ traded pharmaceutical company focused on the development of Cannabinoid-based treatments.
TP Therapeutics, a San Diego-based clinical-stage precision oncology company, has raised $80m in a new funding round led by Foresite Capital and venBio Partners.
AbbVie and Morphic Therapeutic have entered into a research and development collaboration, designed to advance multiple Morphic's oral integrin therapeutics for fibrosis-related indications.
Swiss drugmaker Novartis has agreed to acquire US-based biopharmaceutical firm, Endocyte, in a deal valued at around $2.1bn.
Diurnal Group has decided to put a hold on all activities relating to the US development of its adrenal drug Chronocort following a failure in a recently concluded phase 3 trial in adults with congenital adrenal hyperplasia (CAH).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.